bimzelx solution
ucb canada inc - bimekizumab - solution - 160mg - bimekizumab 160mg
bimzelx solution
ucb canada inc - bimekizumab - solution - 160mg - bimekizumab 160mg
bimzelx
neopharm ltd, israel - bimekizumab - solution for injection - bimekizumab 160 mg / 1 ml - bimekizumab - bimzelx ® is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
bimzelx 160mg/1ml solution for injection pre-filled syringes
ucb pharma ltd - bimekizumab - solution for injection - 160mg/1ml
bimzelx 160mg/1ml solution for injection pre-filled pens
ucb pharma ltd - bimekizumab - solution for injection - 160mg/1ml
bimzelx
ucb pharma s.a. - bimekizumab - psoriasis - immunosuppressants - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards).axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids).ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.